I read with interest the latest significant contributions of the Florence [1] and Mayo Clinic [2] myeloproliferative neoplasm groups to our understanding of essential thrombocytosis (ET). Their contribution of 1000 patients each, fully annotated and followed for decades, provides unique insights into the disease. I would appreciate additional information and the authors’ thoughts regarding the following questions relating to the triple negative (TN) patients in the cohorts:
First, was there a group of TN patients who were also negative for all passenger mutations ie who had no clonal marker at all? If so, did they have a different clinical and hematologic phenotype and/or bone marrow histologic findings to the remainder of the TN patients who did have a clonal marker?
Second, the TN patients in the Florence cohort seem to have a far better prognosis regarding myelofibrosis, leukemia, and thrombosis-free survival and, to some extent, overall survival too. Could the authors postulate a reason for this, specifically, are these bone fide ET patients given their apparent more “benign course?
Finally, the clinical course of the Mayo Clinic TN patients was not as favorable as those from Florence (TN patients fared better only regarding overall survival, leukemia-free survival, and arterial thrombosis-free survival). Do the authors have an explanation for this or are the findings in both cohorts “close enough” to represent an accurate natural TN ET disease course?
References
Loscocco GG, Gesullo F, Capecchi G, Atanasio A, Maccari C, Mannelli F, et al. One thousand patients with essential thrombocythemia: the Florence-CRIMM experience. Blood Cancer J. 2024;14:10. https://doi.org/10.1038/s41408-023-00968-7
Gangat N, Karrar O, Al-Kali A, Begna KH, Elliott MA, Wolanskyj-Spinner AP, et al. One thousand patients with essential thrombocythemia: the Mayo Clinic experience. Blood Cancer J. 2024;14:11. https://doi.org/10.1038/s41408-023-00972-x
Author information
Authors and Affiliations
Contributions
MHE conceived and wrote the content of this Letter to the Editor.
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Ellis, M.H. Queries regarding the two papers each reporting on 1000 essential thrombocythemia patients in BCJ. Blood Cancer J. 14, 89 (2024). https://doi.org/10.1038/s41408-024-01063-1
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41408-024-01063-1